News Archives - Glooko

When you work in diabetes every day, you see the statistics, the market trends, and the clinical realities. When you look a little closer and listen to families navigating diagnosis or clinicians trying to personalize care in overextended health systems, you see something deeper. You see the people behind every data point. This perspective is why I am honored to serve as Chair for the 2026 Boston State of Diabetes event.

Serving as Chair is a responsibility that I care about deeply. Diabetes affects millions of people in this country, and each statistic represents a person, a family, and a community navigating something that touches every part of daily life. The American Diabetes Association (ADA) created the State of Diabetes initiative to elevate those experiences and to bring the diabetes community together in a focused and meaningful way.

This event has grown from eight cities in 2022 to more than thirty across the country today. Boston has always been one of the strongest markets for engagement and thought leadership, and the work that happens here often influences how the program evolves nationally. People come because they are looking for real information and real solutions. They want to hear from experts they can trust. They want to connect with others who understand what life with diabetes looks like and what is changing in the field.

At Glooko, our mission is to give people with diabetes and their care teams tools that make life easier and care more personalized. That work aligns closely with the goals of the ADA. The ADA continues to lead with science, education, advocacy, and support for communities that often need more resources and more transparency around the care they receive. The State of Diabetes creates a space for these priorities to come together. It also creates a place where innovators, clinicians, employers, payers, and community members can learn from one another.

What makes this initiative meaningful to me is the human side of the story. Behind every product, program, or policy are people who are trying to manage a demanding and constant condition. Many are newly diagnosed. Many are caring for a child or an aging parent. Many are clinicians working hard to avoid burnout and keep pace with changing technology and clinical guidance. The event gives us room to talk honestly about those experiences and to highlight the progress that is being made.

As Chair, I hope to help broaden that conversation by inviting new partners to participate, lifting up the important work of the ADA, and encouraging collaboration across the diabetes ecosystem. We have a full year of preparation ahead, and I look forward to sharing updates as we move toward the 2026 event in November.

My goal is simple. I want this initiative to reflect the reality of diabetes today and to shine a light on the ideas and partnerships that can move us forward. People living with diabetes deserve access to care that is reliable, informed, and compassionate. I believe this effort can play a role in creating that future.

The diabetes industry won’t just evolve in 2026. It will continue to undergo a fundamental shift in how care is defined, delivered, and experienced. What was once a landscape dominated by manual tracking and reactive treatments has transformed into a proactive, connected, data-driven ecosystem of diabetes devices, management platforms, manufacturers, digital therapeutics, consumables, educators, and drug therapies.

In 2026, the focus is no longer just about managing diabetes, but about mastering it through integrated data, connected devices and apps, and AI-enabled insights. Glooko’s core mission has always been to bridge the gap between people living with diabetes and healthcare providers through clear, actionable data. This year, we are strengthening that connection by offering innovative solutions like EndoTool, developed by Monarch Medical Technologies, a Glooko Company, and Glooko. Together, these technologies can bridge the continuum of care from inpatient glycemic management to outpatient diabetes management.

To better understand where the industry is going, we asked our experts for their insights and predictions for 2026.

Advancing Diabetes and Glycemic Management in 2026

“The diabetes landscape is set for a massive transformation in 2026. With the launch of the CMS ACCESS Model, we are shifting from simply tracking data to rewarding positive health outcomes during hospital stays. However, as a wave of new CGMs, AI-enabled health software and wearables, and smart pens hits the market, these technologies can quickly overwhelm outpatient care teams. Trusted digital health solutions that bridge these settings, unifying disparate devices into one clear, actionable clinical picture using data, will be key.

This move toward data liquidity means vital information is no longer trapped in a single device or clinical encounter. By integrating inpatient systems with outpatient platforms, care can be more proactive and continuous, especially as new federal quality measures for glycemic safety take full effect this year. We aren’t just looking at numbers anymore; we need to use intelligent, AI-powered insights to make the daily burden of diabetes feel lighter. We’re moving beyond ‘tech for tech’s sake’ and toward a simpler, more connected reality that puts the person before the data.”

– Mike Alvarez, CEO, Glooko

The Rise of New Digital Health Standards and Connected Care

“In 2026, the strategic focus for health systems will shift from fragmented point solutions to a unified continuum of care. As hospitals face tightening margins and new outcome-based payment models like CMS ACCESS, they’ll seek integrated platforms that standardize management for chronic conditions like diabetes across both inpatient and outpatient settings. By consolidating disparate tools into a single, EHR-integrated ecosystem, systems can reduce the cost of maintaining multiple interfaces.

Remote patient monitoring will also see new life in 2026. New programs like the federal Rural Health Transformation Program are bridging the „digital divide” and refocusing on the benefits of connected, digital-forward care. This $50 billion funding allows underserved, rural clinics to adopt advanced AI and remote monitoring tools that were previously limited to urban centers, enabling evidence-based chronic condition management closer to home. By leveraging grants to modernize interoperability and cybersecurity, rural healthcare providers ensure that high-quality, connected diabetes care is no longer determined by a patient’s zip code, but is instead the universal standard.”

– Rich Glenn, President, Connected Care, Glooko

Evolving from Siloed Data Collection to Integrations and Precision Engagement

“This year, we will keep expanding our current support of episodic care to include continuous care, evolving beyond our expertise in data collection to the design of digital ecosystems that bridge the gap between people with diabetes, their device data, and healthcare providers. This shift will replace fragmented data silos with a unified infrastructure where information from diabetes devices and health monitoring apps flow seamlessly into clinicians‘ primary workflows via EHR integrations. We must ensure that continuous data isn’t an overwhelming burden, but an enabling and actionable asset. This collaborative framework alleviates burnout by giving the entire care team an on-demand ‘single source of truth,’ allowing care teams to intervene proactively and spend less time navigating software and more time practicing at the tops of their licenses.

Given recent FDA guidance on wellness wearables and clinical decision support software, we may now be entering a new era of precision engagement fueled by AI. With the latest generations of CGM devices and automated insulin delivery (AID) systems, the field has already moved beyond just seeing data to predicting outcomes and using AI to forecast hypoglycemic events with immediate, context-rich alerts to the person with diabetes. This automation allows patients to manage their care more independently than ever before. However, people with diabetes still benefit from expert teams that can co-pilot their care. There will always be a vital need for care teams to step in when clinical complexity arises or the individual is not achieving their diabetes management goals.”

– Mark Clements, MD, PhD, Chief Medical and Strategy Officer, Glooko

Making Glycemic Safety a Mandatory Protocol

“In 2026, inpatient glycemic safety will transition from a clinical preference to a mandatory system requirement. With CMS now linking reimbursement and quality ratings to the reporting of severe glycemic events, hospitals can no longer rely on the manual vigilance of individual clinicians to manage insulin therapy. Success now requires moving away from fragmented „sliding scale“ protocols and toward purpose-built platforms like EndoTool that ensure consistent, evidence-based dosing and the ability to track outcomes in real time. By treating glycemic management as core safety infrastructure, hospitals and health systems can reduce costly variability, meet new regulatory demands, and allow clinicians to focus on patient care rather than manual calculations.”

– Paul Chidester, MD, Medical Director, Glooko

View Dr. Chidester’s full 2026 outlook on glycemic safety

Solving Specialist Shortages and Clinician Burnout Through Integrated AI and Enhanced Patient Literacy

“Clinician burnout will remain a top priority in 2026, driven in part by the mental exhaustion of managing disjointed tools outside the EHR. This year marks a turning point: embedding integrated data and interoperability within existing workflows will automate administrative tasks, streamline documentation, and provide unified patient views for better clinical decisions. The result will likely be improved provider capacity, proactive care delivery, and sustainable models that optimize both clinical and operational outcomes.

As the endocrinologist shortage intensifies, primary care teams will increasingly leverage specialized healthcare AI tools, including ChatGPT for Healthcare, to reduce administrative burden and enable top-of-scope care delivery, effectively increasing capacity without adding staff.

We will continue to be immersed in the era of the AI-empowered patient. Patients already use tools like ChatGPT Health to synthesize their data, including glucose trends and lab results, before appointments. This increasing health literacy will continue to transform basic data reviews into high-value, collaborative discussions where both clinicians and patients leverage AI for more informed decision-making.”

– Trisha Martinez, BSN, MBA, RN, Senior Director, Clinical Transformation, Glooko

Securing the Digital Health Ecosystem to Thwart AI-Driven Cyberattacks

“In 2026, healthcare data privacy and cybersecurity will undergo a fundamental shift as cyber threats transition to AI-driven, autonomous models. Healthcare organizations must pivot toward ‘agentic resilience,’ a proactive approach leveraging agentic AI, autonomous systems capable of making decisions and executing tasks. These agents can address the vulnerabilities inherent in connected medical ecosystems, such as the possible cyberattack risks present in clinical workflows and medical devices, including connected insulin pumps and CGMs.

To mitigate security risks in 2026, healthcare organizations should also transition toward a robust security framework that replaces traditional passwords with identity-based access control and advanced authentication methods, such as biometric passkeys and MFA. By implementing universal verification, every access request can be rigorously validated regardless of its source, ensuring the integrity of clinical workflows and protecting sensitive health data from unauthorized entry.”

– Ben Chang, Vice President, Security and IT Operations, Glooko

Entering a Highly-Competitive, Integration-First Diabetes Device Ecosystem

“We’re entering the year in a global diabetes landscape that has matured into a competitive, integration-first ecosystem that demands collaboration. With the global diabetes device market projected to exceed $37.9 billion, we are seeing an influx of regional manufacturers offering new device alternatives, giving healthcare providers and people with diabetes a wider array of care choices. This diversification is further accelerated by the mainstream adoption of tubeless patch pumps, CGMs, and non-invasive wearable technologies tailored for the Type 2 diabetes and wellness segments.

From a partnership perspective, these trends reinforce a vital market truth that hardware is no longer a standalone solution. As the number of devices expands, the ultimate competitive advantage belongs to those who prioritize interoperability, integrating effortlessly into the patient’s life and the clinician’s EHR system.”

– Dave Conn, Executive Vice President, Global Alliances, Glooko

Furthering Connected Diabetes Care in Europe

„We’ll continue to move away from disconnected diabetes devices and toward integrated digital ecosystems. As connected care becomes the standard for delivering value, diabetes management will increasingly rely on a coordinated combination of medication, smart hardware, and artificial intelligence, all operating under the supervision of healthcare professionals through structured remote monitoring.

For remote monitoring to be effectively adopted, it must be embedded within national and regulatory frameworks defined by local health authorities. Strict alignment with evolving EU regulations on AI and health data will also remain a central priority.

In terms of devices, the evolution of algorithm-driven AID systems into sophisticated ‘digital companions’ will be the catalyst for a broader diabetes management transformation. By combining predictive AI with remote monitoring, healthcare providers can anticipate patient needs and manage populations remotely, offering a scalable solution to Europe’s workforce challenges by effectively shifting care from hospital settings into the home.“

– Alex Evans, Vice President, Connected Care, EMEA, Glooko

Smarter Technology to Empower People Living with Diabetes

„Over the past few years, managing my diabetes finally felt less like a full-time job and more like a background app running on my phone. We’ve moved away from the constant stress of finger sticks and manual math thanks to the latest AID systems and high-tech sensors that talk to each other better than ever before. These smart systems do the heavy lifting for many, catching highs and lows before they even happen, which takes a huge weight off the shoulders of people with diabetes. Even for those of us who don’t use a pump, connected smart pens can now automatically log every dose, so there’s a lot less guessing and worrying. In 2026, I think we’ll see even more technology that helps further reduce burnout, keep costs more manageable, and maintain time in range — all while letting people think about diabetes a little less.”

– Hadley Horton, Senior Partner Manager, Glooko

Ready to prepare your hospital, health system, or clinic for the rest of 2026?

Contact our team for a demo of our outpatient Glooko diabetes management platform and inpatient EndoTool Glucose Management System.

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.

Every year, the American Diabetes Association (ADA) updates its Standards of Care in Diabetes, the clinical foundation that guides how we screen, diagnose, manage, and support people living with diabetes. The 2026 guidelines are among the most comprehensive to date, with a clear message: diabetes care must evolve to meet rising complexity, widening gaps in care, and the growing urgency to improve outcomes across entire populations.

This year’s recommendations underscore that our work in connected care has never been more important.

Population health requires stronger systems, better data, and integrated teams

The Standards highlight that population health is not simply a measurement framework, but rather a commitment to improving outcomes for groups of people who experience very different barriers, risks, and trajectories. The ADA emphasizes team-based, patient-specific care, timely treatment decisions, reliable data metrics to track quality, and a culture of continuous improvement across health systems.

These priorities mirror what clinicians experience every day: fragmented systems, variable follow-up, and the challenge of navigating high-risk patients without the right tools or insights. Platforms like Glooko, which provide timely insights, structured data access, clinical integration directly into the EHR, and simplified workflows, play a direct role in enabling the proactive care models the ADA calls for. When healthcare professionals manage a large population of patients with diabetes, they often lack a clear, organized, and comprehensive view of patients’ pertinent health data.

To help address this challenge, we designed the new clinic dashboard in the Glooko diabetes management platform. This is critical in providing insights into metabolic factors and indications of clinical risk to facilitate shared decision making conversations in a personalized way, with patients and their support systems.This patient-centric approach helps healthcare providers–including primary care providers, endocrinologists, and nurses, at hospitals, health systems, and clinics–provide individualized care recommendations that are patient-specific.

The Population Metrics section of the new Glooko clinic dashboard helps care teams understand the overall health and engagement of their clinic’s patient population in a centralized and concise view. By centralizing population-level metrics, care teams can more quickly identify disengaged patients, prioritize outreach, and intervene earlier, supporting both quality goals and clinic efficiency.

Glycemic management is becoming more nuanced and more actionable

The 2026 Standards reinforce the importance of individualized glycemic assessment. A1C remains central, but ADA again stresses the clinical value of time in range (TIR), time below range (TBR), and continuous glucose monitoring (CGM) metrics for real-time, person-centered care. We observed similar trends in our 2025 Annual Diabetes Report.

For many clinicians, the challenge is not whether to use CGMs, it’s how to interpret data efficiently and translate trends into action. This is where connected, device-agnostic platforms are essential. Having glucose data delivered in clinically meaningful formats, integrated with insulin dosing, meals, and activity, allows teams to identify risks earlier, adjust therapy faster, and support patients between visits.

This is especially critical for populations highlighted in the Standards: individuals facing food or housing insecurity, young adults with rising complication rates, rural communities with limited access, and older adults with shifting needs. Digital tools do not replace clinicians; they expand their reach.

Inpatient glycemic safety: Operationalizing the ADA’s call for safer insulin use

The 2026 Standards dedicate significant space to preventing hypoglycemia, hyperglycemia, and hyperglycemic crises, events that disproportionately impact people with diabetes during hospitalization or acute illness. ADA guidance reinforces the need for:

Structured insulin protocols
Frequent monitoring to adjust dosing
Systems that minimize variation in clinical decision-making
Approaches that reduce risk during periods of physiologic instability

This is exactly where EndoTool, developed by Monarch Medical Technologies, a Glooko Company, plays a transformative role. EndoTool brings advanced, patient-specific insulin dosing to inpatient settings, enabling dynamic adjustments based on each patient’s evolving physiology. By reducing glycemic variability and supporting timely identification of trends, EndoTool aligns directly with ADA recommendations around individualized glycemic targets, hypoglycemia prevention, and safer transitions of care.

As health systems work to connect inpatient and outpatient data streams, as the Standards increasingly encourage, EndoTool and Glooko have the potential to create a more actionable ecosystem. Patients leave the hospital with a more stable glycemic trajectory, and outpatient teams gain a clearer picture of what occurred during admission, supporting smoother recovery and reduced readmissions.

A vision aligned with where diabetes care is going

Across all 2026 recommendations, a single theme stands out: better outcomes depend on proactive, connected, team-based, data-driven care. The Standards call for more timely therapy changes, broader Diabetes Self-Management Education and Support (DSMES) access, stronger telehealth offerings, and improved system-level accountability.

At Glooko, we’re proud to support clinicians and health systems in delivering on those goals by making diabetes data easier to use, helping teams coordinate more effectively, and empowering people with diabetes with insights that fit their daily lives.

The work ahead is significant, but the path is clearer than ever. Together, we can turn these standards into sustained, measurable improvements in the health of patients and the clinician experience.

As 2025 comes to a close, it is clear that this has been a defining year for Glooko and for the broader evolution of diabetes care. Following the close of our Series F, we entered the year with a clear focus: deliver on our strategy, expand our global impact, and continue building technology that helps make diabetes care more connected, actionable, and human.

Accelerating our Mission through Strategic Leadership and a Connected Care Continuum

Over the past year, we reached several important milestones in support of that goal. We expanded our capabilities through the acquisition of Monarch Medical Technologies and its EndoTool Glucose Management System, bringing together complementary capabilities across outpatient and inpatient diabetes and glycemic management.

We strengthened our ecosystem with the launch of our Abbott FreeStyle Libre integration in the U.S., helping ensure that critical glucose data can flow more seamlessly to people with diabetes and their care teams.

We also reinforced our clinical leadership with the appointment of Mark Clements, M.D., Ph.D., as Chief Medical and Strategy Officer, underscoring our commitment to evidence-based innovation and strong clinical partnership.

Driving Digital Health Adoption in EMEA

We also saw meaningful traction across geographies and care settings.

In EMEA, we continued to expand our presence as health systems look for scalable, interoperable digital solutions to support diabetes care. At the same time, Glooko XT, our remote monitoring solution available only in France, introduced new features and strengthened its gestational diabetes management capability, an area where timely insights and coordinated care are critical for both maternal and fetal outcomes. These areas of momentum reflect the growing demand for digital tools that can support diverse patient populations and clinical workflows.

Further Enhancing our Diabetes Management Platform to Improve Care

On the product front, we continued to invest in tools designed for the realities of care delivery.

The launch of the new Glooko clinic dashboard marked an important step forward in helping clinics and health systems move beyond raw data to clearer insights, enabling more informed, timely decisions at the point of care. Across the organization, we remained focused on bringing teams together around a shared mission and shared standards, ensuring that our growth continues to be purposeful and aligned.

A reality faced by care teams each day is the need for timely, actionable data within existing clinical workflows. That’s why we invested further into our EHR capabilities this year and joined the Epic Showroom to make it easier for hospitals and health systems to seamlessly integrate their EHR with Glooko, helping reduce clinician burnout and optimize clinical workflows.

The Glooko Mobile App for people with diabetes also continued to innovate in 2025 with a redesigned food tracker for more insightful nutrition data and insights, revised insulin cards for more clarity, and viewable GLP-1 doses. These enhancements enable care teams to make more informed and timely treatment decisions between appointments using their patients’ health data – all viewable in one place.

How the U.S. Healthcare System is Moving Toward Data-Driven, Accountable Diabetes Care

These milestones matter, but they are occurring against a broader backdrop of change in healthcare that strongly validates this direction. The latest American Diabetes Association’s Standards of Care reinforce what clinicians and people with diabetes have long understood: technology-enabled management and data-driven insights are now foundational to delivering high-quality diabetes care.

At the same time, policy initiatives such as the CMS ACCESS program signal a growing emphasis on interoperability, data liquidity, and the responsible use of health data to improve outcomes at scale.

Together, these shifts point to a future in which diabetes care is increasingly proactive rather than reactive, and where data is not simply collected, but translated into meaningful action.

Regulatory momentum is reinforcing the importance of consistent, evidence-based glycemic management across care settings. CMS’s upcoming electronic clinical quality measure (eCQM) requirements for inpatient glycemic management, expected to take effect in 2026, reflect a growing emphasis on standardization, measurement, and accountability in hospital-based diabetes care. Solutions like EndoTool are at the forefront of this shift, helping health systems operationalize best practices, support clinical decision-making, and drive more reliable glycemic outcomes at scale.

For healthcare providers and care teams, this evolution brings both opportunity and urgency. As care becomes more continuous and data-rich, success depends on having tools, like Glooko’s EHR integrations, that reduce complexity, surface what matters most, and fit naturally into clinical workflows. The goal is not more data for its own sake, but clearer insight that supports better decisions and more personalized care.

For health systems, the focus is expanding to population-level impact. Managing chronic disease across diverse populations requires platforms that enable earlier intervention, more consistent care, and coordination across settings. Interoperable digital solutions, like Glooko, are becoming essential infrastructure for balancing quality, efficiency, and cost in an increasingly complex care environment.

Leveraging Scalable Healthcare Technology to Deliver Consistent Diabetes Care Around the World

Globally, the stakes are even higher. Diabetes prevalence continues to rise across regions with very different healthcare resources and delivery models. Scalable digital health solutions offer a path to extend evidence-based care, support clinicians, and bring greater consistency to diabetes management worldwide. As global standards and policies evolve, technology will play a central role in enabling more equitable access to high-quality care.

The Road Ahead for Glooko

Looking ahead, our focus at Glooko remains clear. We will continue investing in platforms that turn diabetes data into insight, insight into action, and action into better outcomes. We will deepen partnerships across the ecosystem and stay closely aligned with clinicians, health systems, and people with diabetes as their needs continue to evolve.

2025 was a year of momentum for Glooko. More importantly, it reinforced why our mission matters. As the future of diabetes care continues to take shape, we are energized by the opportunity to help lead the way.

We are proud to share that Glooko has been recognized by The Healthcare Technology Report as one of the Top 50 Healthcare Technology Companies of 2025. This honor reflects the progress we are making toward building a more connected, personalized, and accessible future for people with diabetes and the clinicians who support them.

Each year, this list highlights organizations that are shaping the trajectory of healthcare through innovation and meaningful impact. For Glooko, this recognition reinforces the work taking place across our teams to simplify the complexity of diabetes care. Whether it is bringing data from devices into a single platform, supporting timely clinical decision making, or expanding digital tools that help people manage their diabetes with confidence, our mission has remained constant. We aim to improve patient outcomes through connected care platforms that work in the real world.

This award also reflects how far we have come in strengthening our portfolio. From the continued evolution of the Glooko platform, to the future integration of the inpatient insulin dosing technology of EndoTool, developed by Monarch Medical Technologies, a Glooko Company, to our partnerships that expand clinical value and accessibility, we are building an innovative approach to diabetes management that spans the full care journey. These advancements are the direct result of our teams’ expertise and commitment to the people who rely on our products every day.

Most importantly, this recognition is a reminder of why we do this work. Behind every data point is a person managing a lifelong condition while balancing the demands of life, family, and care. Our responsibility is to meet them where they are with tools that are intuitive, reliable, and informed by real clinical needs.

We are honored to be included among so many forward-thinking healthcare technology leaders. As we look to 2026, we remain focused on delivering solutions that empower clinicians, support health systems, and make life better for people with diabetes around the world.

October is Cybersecurity Awareness Month, but for Glooko, the only diabetes management company with multiple industry-leading security certifications, our commitment to protecting patient health data is a year-round mission.

According to Glooko CEO Mike Alvarez, one of our diabetes management company’s core differentiators is our commitment to patient safety and data privacy, which enables us to build and maintain trust with hospitals, health systems, clinics, and people living with diabetes.

As the healthcare industry faces rising cyberattacks, Glooko understands that securing health data and ensuring the security and privacy of this sensitive information is not just a policy — it’s a core responsibility.

Building a Foundation of Trust Through Security Certifications

Security isn’t a single feature you can switch on; it’s a comprehensive framework built on continuous commitment, sophisticated technology, and rigorous auditing.

As the most secure diabetes management platform, Glooko has invested heavily in achieving and maintaining a number of rigorous global security certifications and standards, which serve as a powerful testament to the maturity and diligence of our security practices that safeguard the sensitive personal and health data of our users with diabetes.

Here are the key standards and certifications that build Glooko’s security backbone:

ISO 27001: This globally recognized information security management standard outlines requirements for an information security management system (ISMS). Achieving this certification means an organization has a systematic approach to managing sensitive company and customer information.
SOC 2 Type II and SOC 3 Certification: These internationally recognized global reporting standards, validated by an auditing firm, verify that Glooko’s controls across its employees, systems, and processes fully secure all customer data, software, and company assets.
HITRUST Risk-based, 2-year (r2) Certification: Achieving this healthcare industry gold standard confirms our stringent, independently-audited security controls meet the highest requirements of frameworks like HIPAA and NIST. This places us in an elite group dedicated to protecting sensitive patient health data. Explore our recent study on strengthening our cyber resilience…
HIPAA Compliance: This U.S. federal law ensures the protection of sensitive patient health information from being disclosed without the patient’s consent or knowledge.
The NHS Digital Data Security and Protection Toolkit (DSPT): For operations in the U.K., this framework ensures that patient data is handled securely and in a way that respects privacy.
GDPR: This comprehensive European Union law gives individuals control over their personal data by setting strict rules for how organizations worldwide must collect, process, and protect that information.

How Diabetes Patient Health Data is Protected on a Day-to-Day Basis

Beyond the certifications, hundreds of controls are implemented to ensure data remains secure at Glooko. Our approach, covering protection, defense, response, and recovery, includes:

Continuous Vulnerability Management: Regular penetration testing and vulnerability scans are conducted to proactively identify and address potential weaknesses in their systems.
Internal Governance: A dedicated governance board oversees our diabetes management company’s policies, ensuring that security and privacy are considered in all decisions.
Employee Training: A core element of any security strategy is the people. Team Glooko receives regular, mandatory training on data security and privacy protocols.
Privileged Access Management: Policies are in place to ensure that only authorized personnel have access to sensitive information.
Secure Software Development Lifestyle (SSDLC): Security code reviews, threat modeling, and static and dynamic code scans are completed during the software development lifecycle

Your Data, Your Control

A crucial part of data privacy is the user’s right to control their information. We make it clear that personally identifiable data is never shared without explicit consent. When using the platform through a healthcare provider, Glooko functions as a part of the healthcare provider’s operations, always adhering to the same stringent privacy standards.

Our Constant Commitment to Protecting Patient Safety

Cybersecurity Awareness Month is a great starting point, but data protection requires constant, evolving, and year-round efforts because threats are always changing.

Through a combination of robust technical controls, a culture of security, and adherence to global standards, Glooko’s commitment to trust and privacy is a fundamental part of our connected care company beyond October.

When healthcare professionals manage a large population of patients with diabetes, they often lack a clear, organized, and comprehensive view of patients’ pertinent health data.

To help address this challenge, we designed the new clinic dashboard in the Glooko diabetes management platform. Available in select countries, the dashboard helps healthcare providers, including primary care providers, endocrinologists, and nurses, at hospitals, health systems, and clinics streamline their diabetes population health management.

Developed for busy healthcare professionals, the new Glooko clinic dashboard is based on TIDE (Timely Interventions for Diabetes Excellence) metrics to help address the challenge of managing a large diabetes patient population. This user-friendly view provides at-a-glance insights into patient population trends and key clinic metrics, making it easier for the entire care team to interpret complex data and guide more efficient decision-making and clinic strategy.

Built on TIDE Metrics for Smarter Diabetes Care

Leveraging evidence-based risk identification logic developed by Stanford researchers to further enhance clinical insights, personalize care, and demonstrate scalable, cost-effective outcomes, the TIDE dashboard, which demonstrated in a 2022 study to reduce screen time for healthcare providers reviewing patient data by 86%, is a powerful tool designed to help clinical teams manage large populations of patients with type 1 diabetes.

The TIDE dashboard uses smart algorithms to analyze and remotely monitor data from continuous glucose monitoring (CGM) devices, helping care teams efficiently and effectively manage their patients’ health. Using essential glucose measures like Time in Range and hypoglycemia, the TIDE model also prioritizes which patients need immediate attention by sorting them by clinical risk, so healthcare providers can focus on those who need it most without sifting through every patient’s data individually.

The TIDE model-based Glooko clinic dashboard offers our professional users a user-friendly way to tackle the challenge of managing a large patient population with three intuitive sections.

Understand Patient Population At-A-Glance

The Population Metrics section of the new Glooko clinic dashboard helps care teams understand the overall health and engagement of their clinic’s patient population in a centralized and concise view. This space displays the total number of patients with diabetes, identifies who is actively monitoring their blood glucose by blood glucose monitors (BGM) or CGM, and shows which patients have completed their Glooko account registration and are actively syncing their health data remotely with our connected care platform.

By centralizing these metrics, this comprehensive section of the dashboard helps healthcare providers shape clinic strategy more efficiently and better understand which patients to contact to activate their Glooko account to make more informed decisions based on synced health data.

Prioritize Care Based on Key CGM Metrics

The CGM Patient Risk Stratification section of the new Glooko clinic dashboard helps healthcare providers prioritize patient care and gives care teams a streamlined view of their patient population, sorted by clinical risk based on key glucose metrics from CGMs. Care teams can easily spot which patients need attention first. The dashboard ranks patients using indicators like Time in Range, Time Below Range, and other key CGM indicators, so healthcare providers can prioritize outreach and interventions based on the most important CGM data, making it easier for them to focus their time on the patients who need it most.

Boost Patient Engagement and Optimize Care

The Engagement Metrics module of the new Glooko clinic dashboard helps healthcare providers spot engagement gaps in their patient population over the past 90 days.

The Patient Account Status section examines the patient population to see if they’ve set-up their Glooko account based on Activated, Invited Pending, Never Invited, and Likely Duplicates. With these key metrics, care teams can quickly see which patients with diabetes haven’t completed the sync to Glooko with their diabetes and health monitoring devices as well as the activation process, allowing for more efficient follow-up and activation.

In the Sync Methods section, care teams can see how patients with diabetes are syncing their data with Glooko. When more health data is synced with Glooko from the cloud, Glooko Mobile App, Transmitter, or Uploader, care teams can make more informed and timely treatment decisions.

Experience Glooko’s New Clinic Dashboard

Ready to see how the intuitive, new Glooko clinic dashboard can optimize diabetes population health management at your clinic, hospital, or health system? Contact our team for a demo.

Today marks an important milestone in our mission to transform diabetes care. I am excited to share that Glooko has acquired Monarch Medical Technologies, creators of the EndoTool® Glucose Management System.

With this acquisition, Glooko is positioned to become the only diabetes management company with the potential to connect the full continuum of care — from home to hospital and back again. By bringing together EndoTool’s proven inpatient insulin dosing technology with Glooko’s leading outpatient platform, we aim to create a future where care is seamless, safer, and more supportive for both people living with diabetes and healthcare providers.

For patients, this means fewer disruptions as they move between settings, reduced risk of dangerous glycemic events, and more confidence that their care is connected. For healthcare providers, it means access to tools that simplify complex insulin management, standardize protocols, and free up time to focus on what matters most, which is caring for people.

This step also sets the foundation for Glooko’s future: using data and AI to help clinicians anticipate risks earlier, personalize care at scale, and improve outcomes under value-based models. By aligning advanced technology with clinical guidelines and EHR workflows, we can help hospitals and health systems deliver higher-quality care while lowering costs.

Our mission has always been clear: to simplify diabetes management, strengthen connections across the care team, and improve lives. This acquisition represents an important stride toward that vision.

Together, we are building a future where diabetes care is more connected, proactive, and patient-centered than ever.

The Glooko 2025 Global Diabetes Report offers a comprehensive look at how real-world data can drive better outcomes in diabetes care. Powered by billions of data points across 30+ countries, this report uncovers meaningful trends in glycemic management, technology adoption, and behaviors among people living with Type 1, Type 2, and gestational diabetes.

From the rise of remote monitoring to the impact of advanced technologies like Continuous Glucose Monitors (CGMs) and Automated Insulin Delivery (AID) systems, this report explores how personalized insights can be used to better inform personalized care, predict risk, and guide clinical decision-making.

Whether you’re a clinician, researcher, or innovator in diabetes management technology, this report highlights how data can be turned into action — helping to shape a smarter, more connected future of diabetes management.

Download the report

At Glooko, we are committed to simplifying diabetes insights and management for people living with diabetes and healthcare providers alike. That’s why our platform is compatible with more than 200 diabetes and health monitoring devices and growing.

As a company, we could not be more pleased to share that we recently expanded our capabilities to integrate with Abbott’s FreeStyle Libre CGMs in the United States. This integration brings glucose data to more clinics and health systems in our all-in-one solution for diabetes management.

This milestone is more than just a technological advancement — it’s about empowering people with Type 1, Type 2, and gestational diabetes, as well as prediabetes, to become active owners in their health. By combining the precision of Abbott’s FreeStyle Libre CGMs with Glooko’s comprehensive platform, we can provide people living with diabetes and their care teams, including endocrinologists and nurses, with a unified, holistic view of diabetes management and irrefutable information.

From glucose trends to lifestyle behaviors like diet and physical activity, this latest integration ensures that critical insights are easily accessible when and where they are needed most. For healthcare providers and health systems, this means the ability to seamlessly access and analyze patients’ CGM data through Glooko and established electronic health record (EHR) solutions, more informed decision-making, and improved patient outcomes. For people living with diabetes, it means greater confidence in their care and health.

As the number of people with diabetes continues to grow, the need for seamless, data-driven solutions has never been greater. Our new integration with Abbott’s FreeStyle Libre CGMs represents a significant step forward in delivering better, more connected care. This partnership is sure to have a positive impact on the millions of people who rely on FreeStyle Libre CGMs and Glooko.